Bone Biology and Anabolic Therapies for Bone: Current Status and Future Prospects

키워드

참고문헌 (89)

1. Aubin JE., "Advances in the osteoblast lineage", Biochem Cell Biol., 76, pp.899~910 (1998)
2. Aubin JE., "Regulation of osteoblast formation and function", Rev Endocr Metab Disord., 2, pp.81~94 (2001)
3. Stein GS., "Molecular mechanisms mediating proliferation", differentiation interrelationships during progressive development of the osteoblast phenotype, 1993, pp.14, 424~442
4. Kim SW., "Intermittent parathyroid hormone administration converts quiescent lining cells to active osteoblasts", J Bone Miner Res., 27, pp.2075~2084 (2012)
5. Baron R., "Molecular mechanisms of bone resorption: therapeutic implications", Rev Rhum Engl Ed., 63, pp.633~638 (1996)
6. Bruzzaniti A., "Molecular regulation of osteoclast activity", Rev Endocr Metab Disord., 7, pp.123~139 (2006)
7. Boyle WJ., "Osteoclast differentiation and activation", Nature., 423, pp.337~342 (2003)
8. Suda T., "Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families", Endocr Rev, 20, pp.345~357 (1999)
9. Hauge EM., "Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers", J Bone Miner Res., 16, pp.1575~1582 (2001)
10. Kristensen HB., "Increased presence of capillaries next to remodeling sites in adult human cancellous bone", J Bone Miner Res., 28, pp.574~585 (2013)
11. Eghbali-Fatourechi GZ., "Characterization of circulating osteoblast lineage cells in humans", Bone., 40, pp.1370~1377 (2007)
12. Eriksen EF., "Remodeling and vascular spaces in bone", J Bone Miner Res., 22, pp.1~6 (2007)
13. Fujikawa Y., "The human osteoclast precursor circulates in the monocyte fraction", Endocrinology., 137, pp.4058~4060 (1996)
14. Yamamoto Y., "Osteoblasts provide a suitable microenvironment for the action of receptor activator of nuclear factor-kappaB ligand", Endocrinology., 147, pp.3366~3374 (2006)
15. Mizoguchi T., "Identification of cell cycle-arrested quiescent osteoclast precursors in vivo", J Cell Biol., 184, pp.541~554 (2009)
16. Muto A., "Lineage-committed osteoclast precursors circulate in blood and settle down into bone", J Bone Miner Res, 26, pp.2978~2990 (2011)
17. Doherty MJ., "Vascular pericytes express osteogenic potential in vitro and in vivo", J Bone Miner Res., 13, pp.828~838 (1998)
18. Howson KM., "The postnatal rat aorta contains pericyte progenitor cells that form spheroidal colonies in suspension culture", Am J Physiol Cell Physiol., 289, pp.C1396~1407 (2005)
19. Matsumoto T., "Therapeutic potential of vasculogenesis and osteogenesis promoted by peripheral blood CD34-positive cells for functional bone healing", Am J Pathol., 169, pp.1440~1457 (2006)
20. Mödder UI., "Skeletal stem", osteoprogenitor cells: current concepts, alternate hypotheses, and relationship to the bone remodeling compartment, 2008, pp.103, 393~400
21. Otsuru S., "Circulating bone marrow-derived osteoblast progenitor cells are recruited to the bone-forming site by the CXCR4", stromal cell-derived factor-1 pathway, 2008, pp.26, 223~234
22. Frost HM., "Bone biodynamics", pp.315~333 (1964), Little, Brown and Company
23. Parfitt AM., "The coupling of bone formation to bone resorption: a critical analysis of the concept and of its relevance to the pathogenesis of osteoporosis", Metab Bone Dis Relat Res., 4, pp.1~6 (1982)
24. Eriksen EF., "Normal and pathological remodeling of human trabecular bone: three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease", Endocr Rev., 7, pp.379~408 (1986)
25. Martin T., "Molecular mechanisms in coupling of bone formation to resorption", Crit Rev Eukaryot Gene Expr., 19, pp.73~88 (2009)
26. Cummings SR., "Denosumab for prevention of fractures in postmenopausal women with osteoporosis", N Engl J Med., 361, pp.756~765 (2009)
27. Gelb BD., "Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency", Science., 273, pp.1236~1238 (1996)
28. Saftig P., "Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice", Proc Natl Acad Sci U S A., 95, pp.13453~13458 (1998)
29. Pennypacker B., "Bone density, strength, and formation in adult cathepsin K (-", -) mice, 2009, pp.44, 199~207
30. Lotinun S., "Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation", J Clin Invest., 123, pp.666~681 (2013)
31. Pennypacker BL., "Cathepsin K inhibitors prevent bone loss in estrogen-deficient rabbits", J Bone Miner Res., 26, pp.252~262 (2011)
32. Cusick T., "Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey", J Bone Miner Res., 27, pp.524~537 (2012)
33. Masarachia PJ., "Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys", J Bone Miner Res., 27, pp.509~523 (2012)
34. Eisman JA., "Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect", J Bone Miner Res., 26, pp.242~251 (2011)
35. Neer RM., "Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis", N Engl J Med., 344, pp.1434~1441 (2001)
36. Frolik CA., "Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure", Bone., 33, pp.372~379 (2003)
37. Ma YL., "Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation", Endocrinology., 142, pp.4047~4054 (2001)
38. Gowen M., "Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats", J Clin Invest., 105, pp.1595~1604 (2000)
39. Fox J., "Plasma levels of parathyroid hormone that induce anabolic effects in bone of ovariectomized rats can be achieved by stimulation of endogenous hormone secretion", Bone., 21, pp.163~169 (1997)
40. John MR., "ATF936, a novel oral calcilytic, increases bone mineral density in rats and transiently releases parathyroid hormone in humans", Bone, 49, pp.233~241 (2011)
41. Misof BM., "Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment", J Clin Endocrinol Metab., 88, pp.1150~1156 (2003)
42. Ma YL., "Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis", J Bone Miner Res., 21, pp.855~864 (2006)
43. Jilka RL., "Molecular and cellular mechanisms of the anabolic effect of intermittent PTH", Bone., 40, pp.1434~1446 (2007)
44. Keller H., "SOST is a target gene for PTH in bone", Bone., 37, pp.148~158 (2005)
45. Martin TJ., "Osteoclast-derived activity in the coupling of bone formation to resorption", Trends Mol Med., 11, pp.76~81 (2005)
46. Gooi JH., "Calcitonin impairs the anabolic effect of PTH in young rats and stimulates expression of sclerostin by osteocytes", Bone., 46, pp.1486~1497 (2010)
47. Tang Y., "TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation", Nat Med., 15, pp.757~765 (2009)
48. Xian L., "Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells", Nat Med., 18, pp.1095~1101 (2012)
49. Canalis E., "Mechanisms of anabolic therapies for osteoporosis", N Engl J Med., 357, pp.905~916 (2007)
50. Horwitz MJ., "Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose", J Clin Endocrinol Metab., 95, pp.1279~1287 (2010)
51. Henry JG., "Parathyroid hormone-related protein-(1-36) is biologically active when administered subcutaneously to humans", J Clin Endocrinol Metab., 82, pp.900~906 (1997)
52. Ferrandon S., "Sustained cyclic AMP production by parathyroid hormone receptor endocytosis", Nat Chem Biol., 5, pp.734~742 (2009)
53. Horwitz MJ., "A comparison of parathyroid hormone-related protein (1-36) and parathyroid hormone (1-34) on markers of bone turnover and bone density in postmenopausal women: the PrOP study", J Bone Miner Res., 28, pp.2266~2276 (2013)
54. "Osteoporos Int.", 2004, 992~997
55. Black DM., "One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis", N Engl J Med., 353, pp.555~565 (2005)
56. Bilezikian JP., "Combination", sequential therapies for anabolic and antiresorptive skeletal agents for osteoporosis, 2006, pp.4, 5~13
57. Delmas PD., "The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate--is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system?", Bone., 16, pp.603~610 (1995)
58. Black DM., "The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis", N Engl J Med., 349, pp.1207~1215 (2003)
59. Finkelstein JS., "The effects of parathyroid hormone, alendronate, or both in men with osteoporosis", N Engl J Med., 349, pp.1216~1226 (2003)
60. Tsai JN., "Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial", Lancet., 382, pp.50~56 (2013)
61. in postmenopausal osteoporosis, "J Bone Miner Res.", 2011, 503~511
62. Pierroz DD., "Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL", J Biol Chem., 285, pp.28164~28173 (2010)
63. Vahle JL., "Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety", Toxicol Pathol., 30, pp.312~321 (2002)
64. Tashjian AH, Jr., "On the interpretation of rat carcinogenicity studies for human PTH(1-34) and human PTH(1-84)", J Bone Miner Res., 23, pp.803~811 (2008)
65. Cosman F., "Daily and cyclic parathyroid hormone in women receiving alendronate", N Engl J Med., 353, pp.566~575 (2005)
66. Li X., "Sclerostin binds to LRP5", 6 and antagonizes canonical Wnt signaling, 2005, pp.280, 19883~19887
67. Semënov M., "SOST is a ligand for LRP5", LRP6 and a Wnt signaling inhibitor, 2005, pp.280, 26770~26775
68. Rawadi G., "BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop", J Bone Miner Res., 18, pp.1842~1853 (2003)
69. Gong Y., "LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development", Cell., 107, pp.513~523 (2001)
70. Babij P., "High bone mass in mice expressing a mutant LRP5 gene", J Bone Miner Res., 18, pp.960~974 (2003)
71. Kato M., "Cbfa1-independentdecrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor", J Cell Biol., 157, pp.303~314 (2002)
72. Krishnan V., "Regulation of bone mass by Wnt signaling", J Clin Invest., 116, pp.1202~1209 (2006)
73. Baron R., "Targeting the Wnt", beta-catenin pathway to regulate bone formation in the adult skeleton, 2007, pp.148, 2635~2643
74. Ke HZ., "Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases", Endocr Rev., 33, pp.747~783 (2012)
75. Yaccoby S., "Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo", Blood., 109, pp.2106~2111 (2007)
76. Clément-Lacroix P., "Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice", Proc Natl Acad Sci U S A., 102, pp.17406~17411 (2005)
77. Kulkarni NH., "Orally bioavailable GSK-3alpha", beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo, 2006, pp.21, 910~920
78. Loots GG., "Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease", Genome Res., 15, pp.928~935 (2005)
79. Balemans W., "Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)", Hum Mol Genet., 10, pp.537~543 (2001)
80. Balemans W., "Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease", J Med Genet., 39, pp.91~97 (2002)
81. van Bezooijen RL., "Bone morphogenetic proteins and their antagonists: the sclerostin paradigm", J Endocrinol Invest., 28, pp.15~17 (2005)
82. Li X., "Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis", J Bone Miner Res., 24, pp.578~588 (2009)
83. Tian X., "Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model", Bone., 48, pp.197~201 (2011)
84. Padhi D, "Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody", J Bone Miner Res., 26, pp.19~26 (2011)
85. McClung MR., "Romosozumab in postmenopausal women with low bone mineral density", N Engl J Med., 370, pp.412~420 (2014)
86. Li X., "Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats", Endocrinology., 152, pp.3312~3322 (2011)
87. Silvestrini G., "Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone", J Mol Histol., 38, pp.261~269 (2007)
88. Leupin O., "Control of the SOST bone enhancer by PTH using MEF2 transcription factors", J Bone Miner Res., 22, pp.1957~1967 (2007)
89. Dong J., "Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity", Cancer Res., 65, pp.1961~1972 (2005)

관련 논문AI추천